ANDA 76650, held by Pharmobedient. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 76650 (Metformin Hydrochloride), held by Pharmobedient, was first approved by FDA on Sep 13, 2005, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 13, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 14, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 14, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 29, 2010 | Supplement 5Labeling | Approved | None posted |
| Mar 9, 2007 | Supplement 3Labeling | Approved | None posted |
| Sep 13, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters